CN1907254A - Cosmetic kreotoxin paste - Google Patents
Cosmetic kreotoxin paste Download PDFInfo
- Publication number
- CN1907254A CN1907254A CN 200510047010 CN200510047010A CN1907254A CN 1907254 A CN1907254 A CN 1907254A CN 200510047010 CN200510047010 CN 200510047010 CN 200510047010 A CN200510047010 A CN 200510047010A CN 1907254 A CN1907254 A CN 1907254A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- creotoxin
- propylene glycol
- composition
- glycerol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a beauty carnitine grease agent, which comprises the following parts: 10%-50% carnitine, 0-10% dimethyl sulfoxide, 1-10% propylene glycol, 0.2%-2% nitrogen ketone, 1-8% glycerin, 0-1.5% perfume, 0-1% dodecyl sodium sulfate, 0-10% sodium tetradecyl sulfate, 10%-20% collagen, 1%-2% vitamin E, 1%-2% vitamin C, 0-0.1% lauric acid, 0-0.1% oleic acid, 1-2% sodium deoxyribonucleotide, 0-20% hydrolytic protein, 0-20% silk protein, 0-8% limonene, 0-10% decyl methyl sulfoxide, 0-2% hexahydrothymol and water.
Description
Technical field
The invention belongs to a kind of cosmetics, particularly a kind of cosmetic kreotoxin paste.
Background technology
Nineteen forty-six, Schanz is the bacillus botulinus .20 later stage sixties in century of purifying crystal shape first, and pediatric ophthalmology doctor Scott imagines the method treatment stravismus by muscular paralysis, the clinical research work of back and Schants cooperation development creotoxin.Scott[1] at first begin in volunteer's body, to inject creotoxin, the treatment spastic strabismus, and succeed.In the end of the year 1997, the A type creotoxin of Schants preparation has passed through the authentication of FDA (Food and Drug Adminstration) (FDA), and is new drug in official approval in 1989, is used for the treatment of the stravismus that the muscle tone obstacle causes, diseases such as blepharospasm.Early 1990s A type creotoxin begins to be used for cosmetic plastic surgery, the dynamic property wrinkle of treatment women's head-ornaments portion.1993, China like product BTX came out, and domestic application also starts from 1993 [2], and over 10 years, A type creotoxin has obtained utilization widely in the cosmetic plastic surgery field.
Creotoxin is a kind of extracellular toxin that the positive anaerobic spore-bearing bacilli of Gram's staining produces in reproductive process, can be divided into 8 types, and wherein A type creotoxin virulence is strong, and is stable, is easy to produce, thereby is applied the earliest.The botulinal crystallization of A type is the complex of neurotoxin and hemagglutinin, relative molecular weight about 90000.Hemagglutinin is kept the form and the space structure of toxin, makes neurotoxin keep stable virulence, and its ultraviolet maximum absorption spectrum 278nm. is stable in acid solution, can spontaneously separate in neutrality or alkaline solution.
The botulinum toxin type A specific action is in the presynaptic neurolemma of the unit of cholinergic motion on every side, the propagation of the zest of inhibition calcium ion mediation and the neural excitation of spontaneous acetylcholine, N﹠M does not all have irritability and conductive infringement, this effect is called the denervation effect, the main mode that body resists chemical denervation effect is the neural axon blastogenesis, this regeneration behavior can the partial interpretation detoxifying function time finiteness, clinical effect was generally kept 3-6 month.
The main application of A type creotoxin in the plastic surgery is: when using Botox (translation) treatment facial spasm disease, find that patient's facial wrinkles obviously alleviates, for example: injection Botox can eliminate glabellar frown lines time the inboard treatment of eyebrow blepharospasm, subsequently, Botox is used successfully in treatment volume band, bridge of the nose portion wrinkle and crows-feet.Be applied to the middle and lower part now gradually and comprise the palpebra inferior wrinkle, nasolabial fold dynamic property gauffer and perioral aging lines etc.
Although injection A type creotoxin has the good wrinkle effect that removes, but in use still have following defective: 1, the administering mode of this injection need be injected at least 12 points even more, and will inject once every half a year, therefore brought huge misery to the patient, made the patient produce very big fear.2, A type creotoxin injection must be kept at-5 ℃ in-20 ℃ environment, uses and operate to keep cryogenic environment, to reduce the loss of biologic activity, therefore brings very big restriction in transportation and injection.3, the patient must arrive specified beauty parlor or hospital injects, and must have experience abundant, and the doctor that technical merit is high just can finish, and brings very big inconvenience to the patient, especially those busy white collar women.4, the expense of great number, per injection needs at least 2000 yuan expense.Based on above shortcoming and restriction, the medical worker is striving to find the way of solution, so that creotoxin better plays a role.
Summary of the invention
The purpose of this invention is to provide a kind of cosmetic kreotoxin paste, stablize at normal temperatures, do not transported the restriction of necessary freezing conditions, can reduce the expense of transportation, can reduce storage cost again.Easy to use, be not subjected to time and environmental limit, removed and injected the pain of bringing to user in the past, accept for people easily; The expense of this dosage form is more much lower than the expense of injection, is easy to promote, and has simultaneously and preserves moisture, and the skin care effect can reach the double effects that not only removes wrinkle but also improve looks.
The objective of the invention is to be achieved through the following technical solutions: the composition and the weight percent of composition are as follows:
Creotoxin A 10%-50%
Dimethyl sulfoxide 0-10%
Propylene glycol 1-10%
Azone 0.2%-2%
Glycerol 1-8%
Spice 0-1.5%
Sodium lauryl sulphate 0-1%
Sodium tetradecyl sulfate 0-10%
Collagen protein 10%-20%
Vitamin E 1%-2%
Vitamin C 1%-2%
Lauric acid 0-0.1%
Oleic acid 0-0.1%
Borneolum Syntheticum 0-0.5%
Deoxyribonucleic acid sodium salt 1%-2%
Hydrolyzed protein 0-20%
Fibroin albumen 0-20%
Limonene 0-8%
Decyl methyl sulfoxide 0-10%
Menthol 0-2%
Surplus is a water
Production method: 1, propylene glycol, glycerol are heated to 80 ℃; 2, creotoxin A, Deoxyribonucleic acid sodium salt fully are dissolved in the water, make mixture one; When 3, propylene glycol and glycerol being cooled to 25 ℃, vitamin E, vitamin C are slowly added wherein, stir while adding abundant mixing, make mixture two; 4, mixture one is slowly poured in the mixture two, put into other composition, stirring simultaneously, after all mixing, fully shook 1 hour; 5, unguentum is made conventional sense, at last packing.
Advantage of the present invention is: stablize at normal temperatures, do not transported the restriction of necessary freezing conditions, can reduce the expense of transportation, can reduce storage cost again.Easy to use, be not subjected to time and environmental limit, removed and injected the pain of bringing to user in the past, accept for people easily; The expense of this dosage form is more much lower than the expense of injection, is easy to promote, and has simultaneously and preserves moisture, and the skin care effect can reach the double effects that not only removes wrinkle but also improve looks.
The specific embodiment
Embodiment 1
Composition and weight percent:
Creotoxin A 30%
Dimethyl sulfoxide 8%
Propylene glycol 6%
Azone 0.2%
Glycerol 8%
Spice 1%
Sodium lauryl sulphate 1%
Collagen protein 11%
Vitamin E 1%
Vitamin C 2%
Lauric acid 0.1%
Deoxyribonucleic acid sodium salt 1.2%
Hydrolyzed protein 15%
Surplus is a water.
Manufacturing process:
1, propylene glycol, glycerol are heated to 80 ℃; 2, creotoxin A, Deoxyribonucleic acid sodium salt fully are dissolved in the water, make mixture one; When 3, propylene glycol and glycerol being naturally cooled to 25 ℃, vitamin E, vitamin C are slowly added wherein, stir while adding abundant mixing, make mixture two; 4, mixture one is slowly poured in the mixture two, put into other composition, stirring simultaneously, after all mixing, fully shook 1 hour; 5, unguentum is made conventional sense, at last packing.
Embodiment 2
Composition and weight percent:
Creotoxin A 11%
Decyl methyl sulfoxide 5%
Azone 0.8%
Propylene glycol 5%
Sodium tetradecyl sulfate 5%
Menthol 1%
Glycerol 4%
Spice 1%
Sodium lauryl sulphate 1%
Collagen egg 19%
Vitamin E 2%
Vitamin C 1%
Lauric acid 0.1%
Deoxyribonucleic acid sodium salt 1%
Fibroin albumen 10%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 3
Composition and weight percent:
Creotoxin A 20%
Dimethyl sulfoxide 5%
Propylene glycol 2%
Azone 1%
Menthol 1%
Glycerol 5%
Limonene 4%
Spice 0.8%
Sodium tetradecyl sulfate 1%
Collagen protein 13%
Vitamin E 1.5%
Vitamin C 1.5%
Oleic acid 0.1%
Deoxyribonucleic acid sodium salt 1.5%
Hydrolyzed protein 10%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 4
Composition and weight percent:
Creotoxin A 25%
Dimethyl sulfoxide 9%
Propylene glycol 4%
Azone 1.5%
Glycerol 4%
Spice 1%
Sodium lauryl sulphate 1%
Collagen protein 17%
Vitamin E 1%
Vitamin C 2%
Lauric acid 0.1%
Deoxyribonucleic acid sodium salt 1%
Hydrolyzed protein 5%
Decyl methyl sulfoxide 3%
Menthol 1%
Fibroin albumen 2%
Limonene 4%
Oleic acid 0.1%
Borneolum Syntheticum 0.3%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 5
Composition and weight percent:
Creotoxin A 35%
Dimethyl sulfoxide 5%
Propylene glycol 9%
Azone 1.9%
Glycerol 2%
Spice 1.4%
Sodium lauryl sulphate 1%
Collagen protein 10%
Vitamin E 1%
Vitamin C 2%
Lauric acid 0.1%
Deoxyribonucleic acid sodium salt 1.8%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 6
Composition and weight percent:
Creotoxin A 12%
Dimethyl sulfoxide 3%
Azone 1%
Glycerol 1%
Propylene glycol 10%
Vitamin E 2%
Vitamin C 1%
Lauric acid 0.1%
Collagen protein 17%
Deoxyribonucleic acid sodium salt 1.9%
Hydrolyzed protein 3%
Decyl methyl sulfoxide 2%
Sodium tetradecyl sulfate 10%
Menthol 1.5%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 7
Composition and weight percent:
Creotoxin A 22%
Dimethyl sulfoxide 10%
Propylene glycol 2%
Azone 1.2%
Spice 0.8%
Collagen protein 18%
Sodium lauryl sulphate 1%
Vitamin E 1.5%
Vitamin C 1%
Deoxyribonucleic acid sodium salt 2%
Hydrolyzed protein 16%
Glycerol 8%
Decyl methyl sulfoxide 7%
Menthol 2%
Fibroin albumen 15%
Limonene 4%
Oleic acid 0.1%
Borneolum Syntheticum 0.5%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 8
Composition and weight percent:
Creotoxin A 40%
Dimethyl sulfoxide 4%
Propylene glycol 7%
Azone 1.2%
Spice 1.2%
Collagen protein 15%
Sodium lauryl sulphate 1%
Vitamin E 1%
Vitamin C 1.3%
Deoxyribonucleic acid sodium salt 1%
Glycerol 8%
Limonene 3%
Oleic acid 0.1%
Borneolum Syntheticum 0.5%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 9
Composition and weight percent:
Creotoxin A 17%
Propylene glycol 1%
Azone 1.7%
Spice 0.1%
Collagen protein 10%
Sodium lauryl sulphate 1%
Vitamin E 1%
Vitamin C 1.7%
Deoxyribonucleic acid sodium salt 1.2%
Glycerol 6%
Decyl methyl sulfoxide 9%
Menthol 2%
Fibroin albumen 18%
Limonene 6%
Oleic acid 0.1%
Borneolum Syntheticum 0.4%
Surplus is a water.
Manufacturing process is with embodiment 1.
Embodiment 10
Composition and weight percent:
Creotoxin A 19%
Propylene glycol 4%
Azone 1.5%
Spice 1.3%
Collagen protein 13%
Vitamin E 1%
Vitamin C 2%
Deoxyribonucleic acid sodium salt 1%
Hydrolyzed protein 8%
Glycerol 5%
Menthol 1%
Fibroin albumen 15%
Oleic acid 0.1%
Borneolum Syntheticum 0.4%
Surplus is a water.
Manufacturing process is with embodiment 1.
Claims (1)
1, a kind of cosmetic kreotoxin paste is characterized in that: the composition and the weight percent of composition are as follows:
Creotoxin A 10%-50%
Dimethyl sulfoxide 0-10%
Propylene glycol 1-10%
Azone 0.2%-2%
Glycerol 1-8%
Spice 0-1.5%
Sodium lauryl sulphate 0-1%
Sodium tetradecyl sulfate 0-10%
Collagen protein 10%-20%
Vitamin E 1%-2%
Vitamin C 1%-2%
Lauric acid 0-0.1%
Oleic acid 0-0.1%
Borneolum Syntheticum 0-0.5%
Deoxyribonucleic acid sodium salt 1%-2%
Hydrolyzed protein 0-20%
Fibroin albumen 0-20%
Limonene 0-8%
Decyl methyl sulfoxide 0-10%
Menthol 0-2%
Surplus is a water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100470101A CN100486557C (en) | 2005-08-05 | 2005-08-05 | Cosmetic kreotoxin paste |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100470101A CN100486557C (en) | 2005-08-05 | 2005-08-05 | Cosmetic kreotoxin paste |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1907254A true CN1907254A (en) | 2007-02-07 |
CN100486557C CN100486557C (en) | 2009-05-13 |
Family
ID=37698594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100470101A Expired - Fee Related CN100486557C (en) | 2005-08-05 | 2005-08-05 | Cosmetic kreotoxin paste |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100486557C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199464B (en) * | 2007-12-14 | 2011-03-23 | 天津天狮生物发展有限公司 | Radix Arnebiae seu Lithospermi hand and fingernail cream and process for preparing same |
CN103479565A (en) * | 2013-09-02 | 2014-01-01 | 吉安市御美丽健康产业有限公司 | Skin cream for removing striae gravidarum |
US20220362126A1 (en) * | 2021-05-13 | 2022-11-17 | Mark A. Foglietti | Cosmetic composition and method |
-
2005
- 2005-08-05 CN CNB2005100470101A patent/CN100486557C/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101199464B (en) * | 2007-12-14 | 2011-03-23 | 天津天狮生物发展有限公司 | Radix Arnebiae seu Lithospermi hand and fingernail cream and process for preparing same |
CN103479565A (en) * | 2013-09-02 | 2014-01-01 | 吉安市御美丽健康产业有限公司 | Skin cream for removing striae gravidarum |
US20220362126A1 (en) * | 2021-05-13 | 2022-11-17 | Mark A. Foglietti | Cosmetic composition and method |
Also Published As
Publication number | Publication date |
---|---|
CN100486557C (en) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1165287C (en) | Compositions contg. antifungal and cationic agent | |
CN1933805A (en) | Cosmetic or dermopharmaceutical compositions of ceramides and polypeptides | |
CN1535677A (en) | Detergent composition | |
CN101052369A (en) | Cosmetics refrigerant composition | |
CN1612722A (en) | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | |
CN1612723A (en) | Local compositions containing enzymes stabilized with inhibitors | |
CN1220492C (en) | External skin composition | |
CN100350029C (en) | Novel surfactants and use thereof | |
CN1136832C (en) | Wrinkling modifiers | |
CN1684594A (en) | Fruit and/or vegetable derived composition | |
CN1663559A (en) | Skin normalizing agents | |
CN1638784A (en) | External compositions for the skin | |
CN1155359C (en) | Compositions contg. antifungal and phospholipid | |
CN1303267A (en) | Surfactant for use in external preparations for skin and external preparation for skin containing the same | |
CN1925838A (en) | Shower oil gels | |
CN1225816A (en) | Moisture retaining agent and external-use agent for skin | |
CN1211177A (en) | Compositions containing an antifungal and a sulfur compound | |
CN1907254A (en) | Cosmetic kreotoxin paste | |
CN1810259A (en) | Gallnut medicine for preventing and treating caries and its extraction process | |
CN1120013C (en) | Medicine for nourishing liver, kidney and hair and beautifying face and its preparing process | |
CN1840177A (en) | Injection liquid of thymic peptide alpha 1 and preparation method thereof | |
CN1679504A (en) | Use of human lysozyme in cosmetics for treating acne | |
CN1673394A (en) | Method for leather-making with Co2 supercritical fluid as medium | |
CN1476332A (en) | Skin external preparation containing pine pollen or pine pollen extract | |
CN1106651A (en) | Kosmetic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090513 Termination date: 20110805 |